Immix Biopharma, Inc.
No SEC Form 4 filings for $IMMX in the last 30 days.
See all $IMMX insider activity →Morgan Stanley initiated Immix Biopharma (IMMX) with an overweight rating and $20 target. The stock is up 168% in a year but down 5.4% recently. Analysts see strong potential in its AL amyloidosis treatment, with high response rates in trials. Q2 2026 earnings showed a wider-than-expected loss. Multiple analysts raised price targets, citing pipeline progress and market potential.
Immix Biopharma (IMMX) closed a $125M offering of 11.36M common shares at $11 each, netting $117.1M after expenses. Proceeds will fund NXC-201 development and general corporate purposes. J.P. Morgan led the offering.
Immix Biopharma, Inc. (IMMX) filed an SEC Form 8-K — Other Events. Exhibit 99.1 Immix Biopharma Announces Pricing of $125 Million Underwritten Offering of Common Stock LOS ANGELES, CA, September 29, 2026 (GLOBE NEWSWIRE) — Immix Biopharma, Inc. (“ImmixBio”, “Company”, “we” or “us” or “IMMX”), a global leader in relapsed/refractory AL Amyloidosis
Over the past 7 days, AlphAI's AI scored 1 news story mentioning IMMX (Immix Biopharma, Inc.). Coverage has skewed bullish: 1 bullish, 0 neutral, and 0 bearish.
Recent IMMX coverage spans corporate actions, technology and financial news.
Analyst upgrade and positive trial data suggest significant upside potential.
The capital raise provides significant funding for clinical development but introduces dilution.
The capital raise provides cash for NXC-201 development but adds dilution.
Strong trial results are likely to boost investor confidence and drive the stock higher.
Positive trial data is likely to lift the stock as investors anticipate regulatory filing and potential market approval.
AlphAI scores every news story that mentions IMMX with an AI model for sentiment and relevance, and aggregates insider trades from Immix Biopharma, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Morgan Stanley initiated Immix Biopharma (IMMX) with an overweight rating and $20 target. The stock is up 168% in a year but down 5.4% recently. Analysts see strong potential in its AL amyloidosis treatment, with high response rates in trials. Q2 2026 earnings showed a wider-than-expected loss. Multiple analysts raised price targets, citing pipeline progress and market potential.
2 min readImmix Biopharma (IMMX) closed a $125M offering of 11.36M common shares at $11 each, netting $117.1M after expenses. Proceeds will fund NXC-201 development and general corporate purposes. J.P. Morgan led the offering.
1 min readImmix Biopharma, Inc. (IMMX) filed an SEC Form 8-K — Other Events. Exhibit 99.1 Immix Biopharma Announces Pricing of $125 Million Underwritten Offering of Common Stock LOS ANGELES, CA, September 29, 2026 (GLOBE NEWSWIRE) — Immix Biopharma, Inc. (“ImmixBio”, “Company”, “we” or “us” or “IMMX”), a global leader in relapsed/refractory AL Amyloidosis
1 min readImmix Biopharma (IMMX) reported an 89% complete response rate in a Phase 2 study of NXC-201 for treating AL amyloidosis, with potential to reach 98%. The study, involving 45 patients, showed no relapses or severe side effects. NXC-201 has received FDA and EMA designations. IMMX stock is down 6.71% at $10.70.
2 min readImmix Biopharma, Inc. (IMMX) filed an SEC Form 8-K — Other Events. Exhibit 99.1 Immix Biopharma Announces 89% Complete Response Rate at Interim Update Across All NEXICART-2 Patients, with MRD-Negativity Indicating Potential to Reach up to 98% Complete Response Rate, Supporting Potential Best-in-Class Therapy for Relapsed/Refractory AL Amyloidosi
2 min readMizuho analyst Graig Suvannavejh named Immix Biopharma (IMMX) as his top September pick, raising the price target to $26 from $15. The upgrade is based on the potential of NXC-201, a drug for relapsed/refractory AL amyloidosis, with projected peak global revenue of $1 billion. Immix shares have gained 133% year-to-date, outperforming the broader biotech sector. The company reported a net loss of $0.18 per share for Q2 2026.
2 min readThe article says convicted fugitive former doctor Ronald Fischer, 70, appeared in Rhode Island court under an alias, after being arrested in July 2024 while working as Chief Medical Officer for Immix Biopharma. It reports Immix filed an SEC Form 8-K stating “Richard Graydon” was terminated and is no longer with the company, and that shareholder law firms are investigating hiring practices.
6 min readAccording to Stat News and an SEC filing by California-based Immix Biopharma, Richard Graydon, an alias for fugitive Ronald Fischer, was arrested July 16 in New York after 20 years on the run. Immix said it terminated Graydon on Friday for reasons unrelated to company activities and expects no material business impact. Atossa previously hired him as interim CMO.
7 min readUS Marshals said fugitive Richard Fischer used the alias Richard Graydon, which matches a doctor and biotech executive Immix Biopharma hired as chief medical officer in March. Immix told the SEC it terminated Graydon on Friday for reasons unrelated to company activities. Immix removed his bio and a hiring press release; STAT could not verify his resume.
6 min readInvesting.com reports Immix Biopharma (IMMX) shares fell 11.6% in morning trading after STAT News said the company’s CMO hired in March 2026 under “Dr. Richard Graydon” was actually Ronald Fischer, a fugitive arrested in July 2026. Immix said in an 8-K that “Graydon” was terminated. The drop came ahead of NEXICART-2 trial topline data in Q3 2026.
6 min read
